Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nesuparib - Jeil Pharmaceuticals

Next Previous
Search
Drug Profile

Nesuparib - Jeil Pharmaceuticals

Alternative Names: JPI-547; NOV 1402; NOV140201; OCN-201

Latest Information Update: 23 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jeil Pharmaceutical
  • Developer Jeil Pharmaceutical; Onconic Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors; Tankyrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Ovarian cancer
  • Phase I Pancreatic cancer
  • No development reported Solid tumours

Most Recent Events

  • 16 Jul 2024 Onconic Therapeutics plans the PENELOPE phase II trial for Endometrial cancer (Combination therapy, Late-stage disease) (PO) in August 2024 (NCT06502743)
  • 05 Apr 2024 Pharmacodynamics data from a preclinical study in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 28 Apr 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in South Korea (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top